Richard Shadyac, president and CEO of ALSAC, the fundraising and awareness organization for St. Jude Children’s Research Hospital, received the 2017 Ellis Island Medal of Honor, an award for individuals who have embraced America’s ideals of patriotism, tolerance, brotherhood and diversity, in a May 13 ceremony on Ellis Island in New York. Presented by the... […]
Roman Petrov, will join the faculty of Fox Chase Cancer Center as assistant professor in the division of thoracic surgery. He will concurrently serve as assistant professor of thoracic medicine and surgery at the Lewis Katz School of Medicine at Temple University. Petrov comes to Fox Chase from Memorial Health System in Marietta, OH, where... […]
The Cancer Prevention and Research Institute of Texas awarded more than $25 million in ten grants funding the CPRIT Scholars program. CPRIT has funded eight First-Time, Tenure-Track Faculty Member grants, one Established Investigators grant, and one Rising Stars grant. To date, CPRIT has awarded 1,132 grants of approximately $1.8 billion. Over 1,200 of these are... […]
FY17 BCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.
FY17 OCRP Program Announcements and General Application Instructions for the following award mechanisms are posted on Grants.gov.
FDA has approved Keytruda (pembrolizumab), an anti-PD-1 therapy, in combination with pemetrexed (brand name Alimta) and carboplatin (pem/carbo), a commonly used chemotherapy regimen, for the first-line treatment of metastatic nonsquamous NSCLC, irrespective of PD-L1 expression.
FDA granted accelerated approval to avelumab (trade name Bavencio) for patients with locally advanced or metastatic urothelial carcinoma whose disease progressed during or following platinum-containing chemotherapy or within 12 months of neoadjuvant or adjuvant platinum-containing chemotherapy.
FDA has approved the Kisqali Femara Co-Pack (ribociclib tablets; letrozole tablets) for the treatment of hormone receptor-positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer in postmenopausal women.
The European Commission has approved the antibody ch14.18/CHO, dinutuximab beta, for the treatment of high-risk neuroblastoma in patients aged 12 months and above.
FDA granted Fast Track designation for Reolysin, an immuno-oncology viral agent, for the treatment of metastatic breast cancer.
